Miao, D., He, B., Jiang, Y., Kobayashi, T., Sorocéanu, M. A., Zhao, J., . . . Karaplis, A. C. (2005). Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1–34. American Society for Clinical Investigation.
Chicago-tyylinen lähdeviittausMiao, Dengshun, et al. Osteoblast-derived PTHrP Is a Potent Endogenous Bone Anabolic Agent That Modifies the Therapeutic Efficacy of Administered PTH 1–34. American Society for Clinical Investigation, 2005.
MLA-viiteMiao, Dengshun, et al. Osteoblast-derived PTHrP Is a Potent Endogenous Bone Anabolic Agent That Modifies the Therapeutic Efficacy of Administered PTH 1–34. American Society for Clinical Investigation, 2005.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.